BeOne Medicines Ltd. Class A
688235.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.21B
Close$
Share Statistics
| Market cap | $20.21 Billion |
|---|---|
| Enterprise Value | $16.33 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 12.67% |
|---|---|
| Return on Assets | 7.15% |
| Return on Invested Capital | 13.78% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.66 |
| Enterprise Value to EBIT | 16.79 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BeiGene Ltd
12,000 employees
CEO: John Oyler BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer ...